To The Moon

I have shared this company before but there were not much interest (see attached article below). After recent correction, $ASCLETIS-B(01672)$ has started moving again. 

In fact, the climb accelerated after the company's latest funds raising exercise. This is obvious not normal, however at the same time, not entirely unusual. Most of time it depends on the secondary offering pricing and investor's group. 

This raising has attracted Singapore GIC! It was a pleasant surprise, at least to me... GIC is a Singapore sovereign fund, with a big reputation to uphold. It is well known as a long term stable investor.

I have own Ascletis for quite a number of years, maybe close to a decade. Once again, I have been early in the game. I entered when Ascletis was going nowhere and nobody wants a slice of it. The founder was just any other CEO. However, he is now a multi-millionaire on his own right! 

As mentioned in the earlier article, Ascletis was progressing well with its drug research. Its later stage obesity drug development has especially been performing well when compared to those drugs in the market. With phase III kicking in, it is another big step in the right direction! 

In fact, the company share price just broke its recent high. I have took back my initial investment. However I am still two legs in the game... for a long time to come. If all the jigsaw bits fall into place, I won't be surprised we have another Chinese giant pharmaceutical company in the making.

@Tiger_comments @TigerStars @Daily_Discussion @TigerClub